Articles by Cecilia Brown
No graft-versus-host disease (GVHD) occurred in patients with multiple myeloma (MM) who received allogeneic CAR-T therapy.
Around 25% of patients with high-risk MDS or AML who received venetoclax plus azacitidine maintenance developed chronic GVHD.
Frailty is strongly associated with worse survival outcomes in patients with chronic graft-versus-host disease (GVHD).
No GVHD exacerbations occurred with a BCMA-directed CAR-T in patients with multiple myeloma.
Donor-derived, CD7-directed, CAR T-cell therapy had “encouraging activity” but led to reversible GVHD in 40% of patients.
Around one-third of patients with TP53-mutated acute leukemias or MDS who underwent HSCT developed chronic GVHD.
No moderate-to-severe chronic GVHD occurred in patients with high-risk hematologic malignancies who received Orca-Q.
Fludarabine plus busulfan led to lower rates of grade III-IV acute GVHD than cyclophosphamide plus busulfan.
Belumosudil combination therapy in a real-world setting “appears safe, tolerable, and effective” for chronic GVHD.
Patients receiving allogeneic HSCT face an average of $1 million in transplant-related costs throughout their lifetimes.
Extensive chronic GVHD occurred in 15% of patients with ALL within 2 years of undergoing allogeneic HSCT.
Patients with closely matched donors who received one type of post-transplant regimen had lower rates of GVHD.
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
Patients with CMML who developed GVHD after transplant were less likely to relapse than patients who did not develop GVHD.
More than half of patients receiving haploidentical HSCT had GVHD, but age was the only predictive factor for survival.
670 Madison Ave.
Manalapan, NJ 07726